MX2022013151A - Inhibicion del crecimiento de cristales de roflumilast. - Google Patents

Inhibicion del crecimiento de cristales de roflumilast.

Info

Publication number
MX2022013151A
MX2022013151A MX2022013151A MX2022013151A MX2022013151A MX 2022013151 A MX2022013151 A MX 2022013151A MX 2022013151 A MX2022013151 A MX 2022013151A MX 2022013151 A MX2022013151 A MX 2022013151A MX 2022013151 A MX2022013151 A MX 2022013151A
Authority
MX
Mexico
Prior art keywords
roflumilast
inhibition
crystal growth
efficacy
roflumilast crystals
Prior art date
Application number
MX2022013151A
Other languages
English (en)
Inventor
David W Osborne
Original Assignee
Arcutis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61027004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022013151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arcutis Inc filed Critical Arcutis Inc
Publication of MX2022013151A publication Critical patent/MX2022013151A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/06—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición de limpieza y un método para usar una composición de limpieza, la composición de limpieza incluye una mezcla de tres emolientes diferentes, los emolientes incluyen un primer éster esteárico, un segundo éster esteárico, y un hidrocarburo ramificado, donde el primer éster esteárico y el segundo éster esteárico son diferentes entre sí.
MX2022013151A 2017-06-07 2019-12-06 Inhibicion del crecimiento de cristales de roflumilast. MX2022013151A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/616,409 US9895359B1 (en) 2017-06-07 2017-06-07 Inhibition of crystal growth of roflumilast
US15/676,356 US9884050B1 (en) 2017-06-07 2017-08-14 Inhibition of crystal growth of roflumilast
US15/676,373 US9907788B1 (en) 2017-06-07 2017-08-14 Inhibition of crystal growth of roflumilast

Publications (1)

Publication Number Publication Date
MX2022013151A true MX2022013151A (es) 2022-12-13

Family

ID=61027004

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014741A MX2019014741A (es) 2017-06-07 2018-06-04 Inhibicion del crecimiento de cristales de roflumilast.
MX2022013151A MX2022013151A (es) 2017-06-07 2019-12-06 Inhibicion del crecimiento de cristales de roflumilast.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019014741A MX2019014741A (es) 2017-06-07 2018-06-04 Inhibicion del crecimiento de cristales de roflumilast.

Country Status (13)

Country Link
US (10) US9895359B1 (es)
EP (1) EP3634380B1 (es)
JP (2) JP6401884B1 (es)
KR (1) KR102607917B1 (es)
CN (2) CN108992673B (es)
AU (1) AU2018282098B2 (es)
CA (1) CA3006836C (es)
EA (1) EA039942B1 (es)
ES (1) ES2975278T3 (es)
IL (1) IL271028B2 (es)
MX (2) MX2019014741A (es)
NZ (1) NZ759871A (es)
WO (1) WO2018226584A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11589880B2 (en) 2007-12-20 2023-02-28 Angiodynamics, Inc. System and methods for removing undesirable material within a circulatory system utilizing during a surgical procedure
US20170136158A1 (en) 2015-10-16 2017-05-18 Angiodynamics, Inc. Systems and Methods for Removing Undesirable Material Within a Circulatory System
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) * 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US10821075B1 (en) * 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
EP3801461A2 (en) * 2018-06-04 2021-04-14 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
DE102019201034B4 (de) 2019-01-28 2023-10-12 Ford Global Technologies, Llc Abgassystem für einen Verbrennungsmotor mit SCR-Kühlung sowie Kraftfahrzeug
CA3166300A1 (en) * 2020-01-31 2021-08-05 David W. Osborne Topical roflumilast formulation having improved delivery and plasma half-life
WO2021226370A1 (en) * 2020-05-07 2021-11-11 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high krafft temperature anionic surfactants
US11707454B2 (en) 2020-12-04 2023-07-25 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
WO2023049809A1 (en) 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
US20230190651A1 (en) * 2021-12-17 2023-06-22 Arcutis Biotherapeutics, Inc. Topical Aerosol Foams
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
AU2022446441A1 (en) 2022-03-14 2024-10-17 Arcutis Biotherapeutics, Inc. Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether
WO2024058848A1 (en) * 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
US20250082618A1 (en) * 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) * 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions
WO2025265054A2 (en) 2024-06-21 2025-12-26 Arcutis Biotherapeutics, Inc. Methods of treatment using topical roflumilast compositions

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482537A (en) 1983-09-19 1984-11-13 Charles Of The Ritz Group Ltd. Skin conditioning composition
AU2259692A (en) 1991-07-03 1993-02-11 Sano Corporation Composition and method for transdermal delivery of diclofenac
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
ATE231410T1 (de) 1994-11-04 2003-02-15 Croda Inc Emulgiermittelzusammensetzungen auf basis von fettalkohol- phosphatestern
GB9618974D0 (en) 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US6379687B2 (en) * 1998-05-28 2002-04-30 Bayer Corporation Inhibiting phase separation in low viscosity water-based pesticide suspensions
US6214322B1 (en) 1999-06-15 2001-04-10 Neutrogena Corporation Self-tanning composition comprising carmine
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
PT1511516E (pt) * 2002-05-28 2009-02-20 Nycomed Gmbh Preparação farmacêutica para aplicação tópica
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
US20060204526A1 (en) 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
MXPA06001713A (es) 2003-08-13 2007-01-26 Qlt Usa Inc Composicion de emulsion que contiene dapsone.
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US6949795B2 (en) 2003-11-13 2005-09-27 Micron Technology, Inc. Structure and method of fabricating a transistor having a trench gate
US20050112162A1 (en) 2003-11-26 2005-05-26 Drader Cathy M. Cosmetic formulation containing sheep's milk and method of making a cosmetic formulation containing sheep's milk
CN1657282A (zh) 2004-02-04 2005-08-24 松下电器产业株式会社 真空绝热材料及其制造方法、保温保冷设备、以及绝热板
DE102004025282A1 (de) 2004-05-19 2005-12-08 Henkel Kgaa Verwendung von speziellen Polyolen zur Kristallisationsinhibierung von Oniumaldehyden bzw. -ketonen
US8338648B2 (en) 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
DE102004046236A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
LT1791791T (lt) 2004-09-27 2019-09-10 Special Water Patents B.V. Vandens valymo būdai ir kompozicijos
CA2584169A1 (en) 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
EP1814509A2 (en) 2004-11-09 2007-08-08 Discus Dental Impressions, Inc. Dental whitening systems comprising transition metal salt activator
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060204452A1 (en) 2005-03-10 2006-09-14 Velamakanni Bhaskar V Antimicrobial film-forming dental compositions and methods
PL1888033T3 (pl) 2005-06-09 2014-09-30 Meda Ab Sposób i kompozycja do leczenia chorób zapalnych
US20070048241A1 (en) 2005-08-30 2007-03-01 Croda, Inc. Emulsifying system
US20070098660A1 (en) 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
JP2007119432A (ja) 2005-10-31 2007-05-17 Ichimaru Pharcos Co Ltd ペルオキシソーム増殖剤応答性受容体活性化剤
US20070207107A1 (en) 2006-03-03 2007-09-06 Gareth Winckle Silicone based emulsions for topical drug delivery
FR2898499B1 (fr) 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
WO2007127158A2 (en) 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
US20070258935A1 (en) 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
AU2007276183A1 (en) 2006-07-17 2008-01-24 Nestec S.A. Stable foam and process for its manufacture
US8715700B2 (en) 2006-07-21 2014-05-06 Dow Pharmaceutical Sciences, Inc. Alpha hydroxy acid sustained release formulation
FR2920967B1 (fr) 2007-09-14 2009-10-23 Sederma Soc Par Actions Simpli Utilisation de l'hydroxymethionine en tant qu'actif anti age
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US7893097B2 (en) 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
JP2009034537A (ja) 2008-10-14 2009-02-19 Takara Standard Co Ltd ミラーキャビネット
AU2010270797B2 (en) 2009-07-08 2015-03-19 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US20110117182A1 (en) 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
JP5576693B2 (ja) * 2010-04-02 2014-08-20 久光製薬株式会社 経皮吸収促進剤、および該経皮吸収促進剤を含有する経皮製剤
US8293288B2 (en) 2011-02-23 2012-10-23 Edna Ma Pain relieving composition
US8512768B2 (en) 2011-02-23 2013-08-20 Miss Smarty Pants Enterprises, Inc. Pain relieving composition
CA2831308A1 (en) 2011-03-31 2012-10-04 Sk Biopharmaceuticals Co., Ltd. Intranasal benzodiazepine pharmaceutical compositions
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
MX365427B (es) 2011-05-03 2019-06-03 Aponia Laboratories Inc Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas.
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
WO2013081565A1 (en) 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
US9606589B2 (en) 2011-11-29 2017-03-28 Intel Corporation Expansion card having synergistic cooling, structural and volume reduction solutions
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
HUE052275T2 (hu) 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
US20140275265A1 (en) 2013-03-12 2014-09-18 Core Products International, Inc. Therapeutic cream for application to skin
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
ES2744542T3 (es) 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CA2915206A1 (en) 2013-06-17 2014-12-24 Contract Pharmaceuticals Limited Non-aerosol foams for topical administration
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
SG11201701292XA (en) 2014-08-27 2017-03-30 Abbvie Inc Topical formulation
SG10202112628UA (en) * 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2017216738A1 (en) 2016-06-15 2017-12-21 Torrent Pharmaceuticals Limited Topical compositions of apremilast
WO2018144093A2 (en) 2016-11-03 2018-08-09 Pinsky Mark A Formulations for improved skin care
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN111212625B (zh) 2017-10-20 2023-05-23 宝洁公司 气溶胶泡沫洁肤剂
EP3801461A2 (en) 2018-06-04 2021-04-14 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
WO2021226370A1 (en) 2020-05-07 2021-11-11 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high krafft temperature anionic surfactants
US11707454B2 (en) 2020-12-04 2023-07-25 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
AU2022446441A1 (en) 2022-03-14 2024-10-17 Arcutis Biotherapeutics, Inc. Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether

Also Published As

Publication number Publication date
EP3634380B1 (en) 2024-01-10
IL271028B2 (en) 2024-04-01
US9884050B1 (en) 2018-02-06
AU2018282098A1 (en) 2019-12-19
US20190015398A1 (en) 2019-01-17
CN108992673B (zh) 2020-11-10
US9895359B1 (en) 2018-02-20
KR102607917B1 (ko) 2023-11-29
US9907788B1 (en) 2018-03-06
EA039942B1 (ru) 2022-03-30
US11793796B2 (en) 2023-10-24
EP3634380A1 (en) 2020-04-15
US20240335436A1 (en) 2024-10-10
US10105354B1 (en) 2018-10-23
MX2019014741A (es) 2020-08-03
NZ759871A (en) 2023-07-28
IL271028A (en) 2020-01-30
WO2018226584A1 (en) 2018-12-13
JP2018203736A (ja) 2018-12-27
CN112263577B (zh) 2024-07-09
JP2018203769A (ja) 2018-12-27
CA3006836A1 (en) 2018-08-01
US12257242B2 (en) 2025-03-25
CN112263577A (zh) 2021-01-26
EA201992806A1 (ru) 2020-05-15
JP7242222B2 (ja) 2023-03-20
US20180353490A1 (en) 2018-12-13
BR112019025748A8 (pt) 2022-12-13
BR112019025748A2 (pt) 2020-06-23
JP6401884B1 (ja) 2018-10-10
CA3006836C (en) 2019-06-11
ES2975278T3 (es) 2024-07-04
IL271028B1 (en) 2023-12-01
US10940142B2 (en) 2021-03-09
AU2018282098B2 (en) 2024-05-23
CN108992673A (zh) 2018-12-14
NZ790834A (en) 2023-09-29
AU2018282098A8 (en) 2020-01-02
US20250235435A1 (en) 2025-07-24
US12336983B2 (en) 2025-06-24
KR20200016940A (ko) 2020-02-17
EP3634380C0 (en) 2024-01-10
US20230414589A1 (en) 2023-12-28
US10172841B2 (en) 2019-01-08
US20210244718A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
MX2022013151A (es) Inhibicion del crecimiento de cristales de roflumilast.
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MY177994A (en) Therapeutically active compounds and their methods of use
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
IN2013MU01696A (es)
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
TW201613578A (en) Pharmaceutical combinations
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2021010286A (es) Formas de dosificacion de la hormona del crecimiento de accion prolongada con eficacia superior a la somatropina diaria.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX385881B (es) Forma de dosificacion de alivio prolongado
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
PH12018500096A1 (en) Mdm2 inhibitors for treating uveal melanoma
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MY199579A (en) New use of isoquinoline derivatives for diabetic wound healing
HK1233909A1 (en) Pharmaceutical compositions of therapeutically active compounds
HK1233185A1 (en) Pharmaceutical compositions of therapeutically active compounds